Clinical trials: Patients With Diabetes.
Diabetic Nephropathy
To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy
Phase 2 clinical study to evaluate of the efficacy and safety of DW1029M on microalbuminuria in Patients With Diabetic Nephropathy
- Trial name
- NCT01935167
- Testing
- DW1029M 600mg, DW1029M 1200mg
- Where
- South Korea
- Volunteers
- 158 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Diabetes, Diabetes Mellitus, Type 1
Observational Study of Patients With Diabetes Using Levemir® FlexPen®
This study is conducted in Asia. This study is a prospective, open, uncontrolled, observational surveillance study with Levemir® FlexPen® conducted in Korea.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00670683
- Testing
- insulin detemir
- Where
- South Korea
- Volunteers
- 797 people
- Sponsor
- Novo Nordisk A/S
Diabetic Complication
YJP-14 Capsules for the Treatment of Endothelial Dysfunction in Patients With Diabetes Mellitus
The purpose of this study is to evaluate the safety and efficacy of YJP-14 capsules for the treatment of endothelial dysfunction in patients with diabetes mellitus.
- Trial name
- NCT01836172
- Testing
- YJP-14
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Han Wha Pharma Co., Ltd.
Type 2 Diabetes Mellitus
Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus
This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus.
- Trial name
- NCT00694057
- Testing
- HE3286
- Where
- 22 sites in United States
- Volunteers
- 164 people
- Sponsor
- Harbor Therapeutics
Erectile Dysfunction, Diabetes Mellitus
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction
Erectile dysfunction (ED) is defined as penile erection that is insufficient and unsustainable for a satisfactory sexual performance.
- Trial name
- NCT05884957
- Testing
- Nitric oxide synthase gene
- Where
- Egypt
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Egymedicalpedia
Type 2 Diabetes
Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients
The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with Sitagliptin.
- Trial name
- CMAS (NCT02173457)
- Testing
- Chiglitazar, Sitagliptin
- Where
- 37 sites in China
- Volunteers
- 740 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Diabetes, Diabetes Mellitus, Type 2
Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.
This trial is conducted in the United States of America (USA). The study will compare A1C reduction achieved in patients receiving biphasic insulin aspart 70/30 once or twice daily to patients receiving exenatide twice daily.
- Trial name
- NCT00313001
- Testing
- biphasic insulin aspart, exenatide
- Where
- United States
- Volunteers
- 373 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Malaysia
This study is conducted in Asia. The aim of this non-interventional study is to evaluate the current status of diabetes management, control, and complications in subjects with type 2 diabetes in Malaysia.
- Trial name
- DiabCare Asia (NCT01934673)
- Testing
- No treatment given
- Where
- Malaysia
- Volunteers
- 1,668 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)
To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (based on change in HbA1c from baseline to 24 weeks) when administered in combination with mealtime insulin lispro.
- Trial name
- INSTRIDE 1 (NCT02227862)
- Testing
- Mylan's insulin glargine, Lantus®
- Where
- 162 sites in United States, Canada and 9 more
- Volunteers
- 558 people
- Sponsor
- Mylan Inc.
Type 2 Diabetes (T2DM)
A Study of BGM0504 in Early T2DM With Obesity
This trial is conducted in China. The aim is to compare BGM0504 Injection 15 mg with semaglutide 1.0 mg in Chinese T2DM patients with obesity and inadequate control despite diet and exercise.
- Trial name
- NCT07743983
- Testing
- BGM0504, semaglutide
- Where
- China
- Volunteers
- 372 people
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Type 2 Diabetes Mellitus
A Study of the Current Medical Practice and Outcomes in the Treatment of Type 2 Diabetes Mellitus in an Office Setting (MK-0431-199)
The purpose of this study is to collect information of the risk profile of patients with type 2 diabetes mellitus, their treatment concerning meeting the guidelines for treatment of diabetic patients type 2 published by the…
- Trial name
- SIRTA (NCT01409213)
- Volunteers
- 1,523 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
The aim of this study is to investigate the efficacy, safety and tolerability of BI 10773 compared to placebo and sitagliptin given for 24 weeks as monotherapy in patients with T2DM with insufficient glycaemic control.
- Trial name
- NCT01177813
- Testing
- BI 10773, BI 10773 open label
- Where
- 124 sites in United States, Belgium and 7 more
- Volunteers
- 986 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Safety and Efficacy of Empagliflozin (BI 10773) and Sitagliptin Versus Placebo Over 76 Weeks in Patients With Type 2 Diabetes
This study will investigate the efficacy and long term safety and tolerability of BI 10773 in type 2 diabetic patients.
- Trial name
- NCT01289990
- Testing
- BI 10773, Sitagliptin 100mg
- Where
- 243 sites in United States, Belgium and 17 more
- Volunteers
- 2,705 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus
The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to once-daily insulin glargine in participants with type 2 diabetes mellitus who have inadequate glycemic control with 1 or 2 oral…
- Trial name
- AWARD-CHN2 (NCT01648582)
- Testing
- Dulaglutide, Insulin glargine, Metformin
- Where
- 30 sites in China, Mexico and 2 more
- Volunteers
- 774 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Study of LY3025876 in Participants With Diabetes
The main purpose of this study is to assess the safety and tolerability of LY3025876 given alone (Part A) and in combination with liraglutide (Part B) in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT01870297
- Testing
- LY3025876, Liraglutide
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of combination therapy with dulaglutide and insulin in Japanese participants with type 2 diabetes.
- Trial name
- NCT02750410
- Testing
- Dulaglutide
- Where
- 25 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Efficacy and Safety of Lobeglitazone Versus Sitagliptin
Efficacy and Safety of Lobeglitazone versus Sitagliptin in inadequately controlled by Metformin alone Type 2 Diabetes mellitus Patients with Metabolic syndrome.
- Trial name
- NCT02480465
- Testing
- Lobelitazone 0.5mg, Sitagliptin 100mg
- Where
- South Korea
- Volunteers
- 248 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Diabetes Mellitus, Type 2
Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes
This is a Phase 4, prospective, open label, randomized, parallel controlled multicenter trial in which metformin extended release (XR) will be compared with metformin immediate release (IR) for the gastrointestinal tolerability…
- Trial name
- CONSENT (NCT02252965)
- Testing
- Metformin IR, Metformin XR
- Where
- Germany
- Volunteers
- 532 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Diabetes Mellitus
Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes
The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or amputation in patients with…
- Trial name
- PROactive (NCT00174993)
- Testing
- Pioglitazone
- Where
- 19 sites in Austria, Belgium and 17 more
- Volunteers
- 4,373 people
- Sponsor
- Takeda
Type 2 Diabetes
MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes
This Phase III clinical trial will examine the safety, tolerability, and efficacy of the addition of MK-0431/ONO-5435 to Japanese patients with Type 2 Diabetes mellitus who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT01517321
- Testing
- MK-0431/ONO-5435
- Where
- 6 sites in Japan
- Sponsor
- Ono Pharmaceutical Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.